Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part)
Phase 1/2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 28/100
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis
Conditions
Amyotrophic Lateral Sclerosis
Trial Timeline
Mar 19, 2019 → Mar 31, 2024
NCT ID
NCT04744532About Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part)
Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) is a phase 1/2 stage product being developed by Pfizer for Amyotrophic Lateral Sclerosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04744532. Target conditions include Amyotrophic Lateral Sclerosis.
What happened to similar drugs?
2 of 18 similar drugs in Amyotrophic Lateral Sclerosis were approved
Approved (2) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
9
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04744532 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 17 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 35 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 18 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 38 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 38 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 40 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 35 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 35 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 36 |
| TCH346 | Novartis | Phase 2 | 35 |
| VHB937 | Novartis | Phase 2 | 39 |
| TCH346 | Novartis | Phase 2 | 35 |
| TCH346 | Novartis | Phase 2 | 35 |
| BLZ945 | Novartis | Phase 2 | 27 |
| TRO19622 | Roche | Phase 2/3 | 38 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 40 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 35 |
| DNL747 + Placebo | Sanofi | Phase 1 | 21 |